摘要
非酒精性脂肪肝是最常见的慢性肝病之一,全球发病率高达25%。其中非酒精性脂肪肝炎(nonalcoholic steatohepatitis,NASH)可导致肝硬化和肝癌的发生,是终末期肝病和肝移植的主要原因之一。NASH发病机理复杂,目前尚无有效药物。因此,巨大的市场需求使NASH新药研发成为全球制药公司追逐的热点。目前在研的新型治疗药物主要针对代谢紊乱、氧化应激、炎症、细胞凋亡、肠道微生物群紊乱及纤维化等NASH相关发病机制,并有多个针对不同靶点的新药处于临床后期研究阶段,这些进展将为NASH提供新的治疗手段。本文总结了NASH发病机制及相关药物,并重点综述潜在的NASH治疗靶点及药物研究进展。
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases,with a global incidence of up to 25%.Nonalcoholic steatohepatitis(NASH),which subsequently causes fibrosis cirrhosis and hepatocellular carcinoma,is one of the leading causes of end-stage liver disease and liver transplantation.The pathogenesis of NASH is complex and there is no approved pharmacotherapy.Therefore,the huge market demand makes NASH drug research and development a hotspot for global pharmaceutical companies.Currently,new therapeutic drugs under development mainly target metabolic disorders,oxidative stress,inflammation,apoptosis,intestinal microbiome disorders,fibrosis and other NASH related pathogenesis,and a number of new drugs based on different targets are in the late stage of clinical research.These development will provide new therapy for NASH.This paper summarized the pathogenesis of NASH and related drugs,with emphasis on potential NASH therapeutic targets and drug research progress.
作者
周宗涛
邓利明
胡丽君
任强
张陆勇
李政
ZHOU Zong-tao;DENG Li-ming;HU Li-jun;REN Qiang;ZHANG Lu-yong;LI Zheng(School of Phamacy,Guangdong Pharmaceutical University,Guangzhou 510006,China;Guangdong Key Laboratory of New Drug Discovery and Evaluation,Guangdong Pharmaceutical University,Guangzhou 510006,China;Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems,Guangdong Pharmaceutical University,Guangzhou 510006,China;Jiangsu Key Laboratory of Drug Screening,China Pharmaceutical University,Nanjing 210000,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第12期1363-1374,共12页
Chinese Journal of New Drugs
基金
国家自然科学基金资助项目(81803341)
广东省自然科学基金资助项目(2018A030313445)。
关键词
非酒精性脂肪肝病
氧化应激
炎症
肝纤维化
non-alcoholic fatty liver disease
oxidative stress
inflammation
liver fibrosis
